
How ICH Oversight Changes and AI Are Shaping the Future of Clinical Trials
New ICH revisions are redefining what effective trial oversight looks like, placing new emphasis on transparency, proactive risk management, and operational accountability. Artificial intelligence (AI) is reshaping oversight—through predictive insights, automated analytics and unified platforms like the Clinical Decision Suite—to help sponsors not only meet evolving compliance expectations but also drive smarter, more efficient trial delivery.
In this webinar, you’ll discover:
- What these changes mean for sponsors and the wider industry
- Key emerging oversight priorities, including insights into the recently released ICH E6 (R3) revisions and their implications for clinical trial oversight
- Strategies for sponsors to adapt to changing compliance requirements and enhance trial management
- How AI is transforming clinical trial oversight with predictive insights, automated analytics, and integrated platforms like the Clinical Decision Suite
Speakers:
Chris Axford
Sr. Director, Business Insights, PPD clinical research business of Thermo Fisher Scientific
Johnathan Aceves
Director Regulatory Affairs, PPD clinical research business of Thermo Fisher Scientific